替吉奥持续低剂量口服联合小剂量TACE治疗原发性肝癌疗效观察

Clinical observation on treatment of primary hepatocarcinoma patients with continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE

目的探讨替吉奥持续低剂量口服联合小剂量经导管肝动脉化疗栓塞(TACE)治疗原发性肝癌的疗效及不良反应。方法选择92例不能或不愿外科手术的原发性肝癌,分为两组,各46例。治疗组为替吉奥持续低剂量口服联合小剂量TACE;对照组为小剂量TACE,按预定方案治疗后复查血管造影(DSA)及CT,评价肿瘤新生血管及肿瘤染色情况、KPS评分、术后不良反应和并发症情况,计算患者的肿瘤无进展生存时间(PFS)及3个月、6个月、1年和2年的生存率。结果 2次TACE后复查CT及DSA,治疗组肿瘤新生血管和肿瘤染色显著少于对照组(P<0.05),两组不良反应及并发症发生率相近(P>0.05),治疗前后KPS评分差异无统计学意义(P>0.05)。治疗组患者PFS及1年、2年的生存率均优于对照组(P<0.05)。结论替吉奥持续低剂量口服联合小剂量TACE治疗原发性肝癌有效。

Objective To evaluate the efficacy and adverse reaction of continuous low-dose oral Tegafur,Gimeracil and Oter- acil Potassium Capsules in combination with small dose of transcatheter arterial chemoembolization（TACE） in the treatment of pri- mary hepatocarcinoma patients. Methods A total of 92 primary hepatocarcinoma patients who were unable or unwilling to surgery. Patients were divided into treatment group and control group, with each consisted of 46 cases. The treatment group was given con- tinuous low-dose oral Tegafur, Gimeracil and Oteracil Potassium Capsules in combination with small dose of TACE,and the control group was given small dose TACE. All study subjects were reviewed DSA and CT. tumor angiogenesis and tumor staining,Karnof- sky Performance Scores（KPS）, postoperative adverse events and complications was evaluated. PFS and the survival rate of three months,six months,one year and two years was estimated. Results Tumor angiogenesis and staining were significantly lower in treatment group than those of the control group（P〈0.05）. Patients in the two groups had the same rates of side effects and com- plications（P〉0.05）. KPS scores in the two groups had no significant difference before and after treatment（P〉0.05）. PFS, one year and two years survival rate were better in treatment group than in the control group（P〈0.05）. Conclusion Combined appli- cation of continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE was significantly su- perior to TACE alone in the treatment of primary hepatocarcinoma patients.